Clinical trial · Interventional
Novel Approaches to Target MECOM/EVI1 in AML
Novel Approaches to Target MECOM/EVI1 in Acute Myeloid Leukemia
NCT05839392CI-TRIAL-00072630recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an academic, no-profit, multicenter, biological, non-pharmacologic study aimed at characterizing genome, transcriptome and proteome of patients affected by AML with MECOM or atypical 3q26 rearrangements.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| AML, Adult | Adult Acute Myeloid Leukemia | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biological characterization of AML with MECOM or atypical 3q26 rearrangements | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Identification of MECOM/EVI1 regulators or downstream effectors potentially druggable
- timeFrame
- At baseline
- description
- To assess the number of regulators or effectors of MECOM/EVI1
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * AML with MECOM or atypical 3q26 rearrangements. * Age ≥18. * Signed written informed consent according to ICH/EU/GCP and national local laws. Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.